Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China

OBJECTIVE: The objective of this study was to evaluate the comparative cost-effectiveness of lenvatinib (LEN) plus transarterial chemoembolisation (TACE) (LEN-TACE) and LEN alone to treat advanced hepatocellular carcinoma (HCC) from the perspective of the Chinese healthcare system. DESIGN: A three-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wei, Wan, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533713/
https://www.ncbi.nlm.nih.gov/pubmed/37751954
http://dx.doi.org/10.1136/bmjopen-2023-074245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533713/
https://www.ncbi.nlm.nih.gov/pubmed/37751954
http://dx.doi.org/10.1136/bmjopen-2023-074245

Ejemplares similares